Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Lumira Ventures is a life sciences venture capital firm based in Toronto, Canada, founded in 2007 after a management buyout of MDS Capital. The firm has raised over $6 billion for its portfolio companies, which include more than 100 startups. Lumira operates across North America with offices in Toronto, Montreal, Vancouver, and Boston.
Lumira Ventures invests in therapeutic products and medical devices throughout the development continuum, from early-stage therapeutics to late clinical and revenue-generating medical devices. The firm targets a wide range of therapeutic areas, including oncology, cardiology, and pain management, focusing on solutions that enhance patient outcomes and reduce healthcare costs.
Notable portfolio companies include Endotronix, acquired by Edwards Lifesciences; OpSens Medical, set to be acquired by Haemonetics for $345 million; Bardy, acquired by Hillrom for $375 million; and Engage Therapeutics, acquired by UBC for up to $270 million. Other significant companies include Aurinia Pharmaceuticals and Zymeworks.
Submit your pitch through their form at lumiraventures.com.
Yes, Lumira Ventures often leads investment rounds, particularly in early-stage companies within the life sciences sector.
The firm actively participates in follow-on investments to support portfolio companies as they progress through their development stages.
Lumira Ventures has raised over $6 billion for its portfolio companies, indicating a significant capacity for investment across various stages.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.